Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02126774 · ClinicalTrials.gov registry record

The Human Epilepsy Project

A clinical trial, sponsored by NYU Langone Health.

Completed
Registry status
488
Enrollment target

NCT02126774: Completed study, sponsored by NYU Langone Health.

NCT02126774 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 488 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02126774 has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
488 participants
Enrollment target

Study Summary

HEP is a five-year, prospective, observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy.

Trial Details

FieldValue
Enrollment Target 488 participants
Start Date 2012-07
Est. Completion 2021-07-01
NYU Langone Health

1,164 total trials

What the finished NCT02126774 record still lists

NCT02126774 is an observational study that tracks outcomes without assigning an intervention. The registered 488 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02126774 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02126774 about?

NCT02126774 is a clinical study titled "The Human Epilepsy Project". HEP is a five-year, prospective, observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy.

What is the current status of trial NCT02126774?

This trial is currently completed. The enrollment target is 488 participants. The study started on 2012-07. Estimated completion is 2021-07-01.

Who is sponsoring clinical trial NCT02126774?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05154669 · 488 participants · Phase 3

    Integrating Financial Coaching and Smoking Cessation Coaching

  • NCT06532877 · 488 participants · NA

    Telephone Support in Advanced Gastrointestinal Cancer

  • NCT06602479 · 488 participants · Phase 2

    A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  • NCT06794983 · 488 participants · NA

    Calls and Coordination for Transitions of Care at Re-entry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02126774, the US trial registry maintained by the National Library of Medicine. NCT02126774 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.